Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $23.80 Consensus PT from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has received a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $23.80.

Several equities analysts have recently weighed in on LXEO shares. HC Wainwright increased their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 14th. Leerink Partners reduced their price objective on Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research report on Wednesday, November 13th. Finally, Chardan Capital boosted their price target on Lexeo Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th.

Insiders Place Their Bets

In related news, CEO Richard Nolan Townsend sold 5,000 shares of Lexeo Therapeutics stock in a transaction on Thursday, October 10th. The shares were sold at an average price of $8.10, for a total transaction of $40,500.00. Following the transaction, the chief executive officer now owns 120,695 shares in the company, valued at approximately $977,629.50. The trade was a 3.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 10,000 shares of company stock worth $80,550 over the last quarter. 4.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Lexeo Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Exome Asset Management LLC purchased a new position in Lexeo Therapeutics in the 3rd quarter worth approximately $797,000. Barclays PLC boosted its holdings in shares of Lexeo Therapeutics by 162.2% during the 3rd quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after purchasing an additional 31,057 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Lexeo Therapeutics by 86.5% during the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after purchasing an additional 256,635 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new position in shares of Lexeo Therapeutics during the third quarter valued at about $11,307,000. Finally, Jane Street Group LLC lifted its position in shares of Lexeo Therapeutics by 33.3% in the third quarter. Jane Street Group LLC now owns 35,677 shares of the company’s stock worth $323,000 after buying an additional 8,918 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Stock Up 2.3 %

Shares of Lexeo Therapeutics stock opened at $6.35 on Monday. Lexeo Therapeutics has a twelve month low of $5.77 and a twelve month high of $22.33. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $7.82 and its 200 day moving average is $10.73. The company has a market cap of $209.97 million and a price-to-earnings ratio of -2.01.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.